Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN027
MIFTS: 62

Adenomyosis

Categories: Muscle diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenomyosis

About this section

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 58 12 77 54 45 15 17
Endometriosis of Uterus 12 15 74
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM:

58
Inheritance:
autosomal vs. x-linked dominant


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Reproductive diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:288
OMIM 58 600458
ICD9CM 36 617.0
MeSH 45 D062788
NCIt 51 C6996
SNOMED-CT 69 76376003
ICD10 34 N80.0
MedGen 43 C0341858
UMLS 74 C0341858
Sources

Summaries for Adenomyosis

About this section
NIH Rare Diseases : 54 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine anomalies and adenosarcoma. An important gene associated with Adenomyosis is PGR (Progesterone Receptor), and among its related pathways/superpathways are GPCR Pathway and Nanog in Mammalian ESC Pluripotency. The drugs Ketorolac and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include uterus, pituitary and testes, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : 58 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 77 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Sources

Related Diseases for Adenomyosis

About this section

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 31.5 CDH1 CYP19A1 ESR1 PGR VEGFA
2 adenosarcoma 30.4 ESR1 MME PGR
3 endometrial adenocarcinoma 30.2 ESR1 HOXA10 PGR VEGFA
4 leiomyoma 30.2 CYP19A1 ESR1 GNRH1 MME PGR
5 endometrial stromal sarcoma 30.1 CYP19A1 ESR1 MME PGR
6 endometriosis 30.0 CYP19A1 ESR1 GNRH1 HOXA10 PGR PTGS2
7 intravenous leiomyomatosis 30.0 ESR1 MME
8 leiomyomatosis 30.0 ESR1 GNRH1 PGR
9 myoma 29.9 CYP19A1 ESR1 GNRH1 HOXA10 PGR
10 endometriosis of ovary 29.6 CYP19A1 ESR1 HOXA10 PGR
11 breast fibroadenoma 29.6 CYP19A1 ESR1 MME PGR
12 endometrial cancer 28.2 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MME
13 breast cancer 28.1 VEGFA TIMP2 PTGS2 PRL PGR MMP9
14 adenocarcinoma 10.6
15 light chain deposition disease 10.5 MMP2 MMP9
16 female reproductive endometrioid cancer 10.5 ESR1 PGR
17 vestibular gland benign neoplasm 10.5 ESR1 PGR
18 bartholin's gland adenoma 10.5 ESR1 PGR
19 vulvar syringoma 10.4 ESR1 PGR
20 lung leiomyoma 10.4 ESR1 PGR
21 extracranial arteriovenous malformation 10.4 MMP2 MMP9
22 glassy cell carcinoma of the cervix 10.4 ESR1 PGR
23 focal myositis 10.4 MMP2 MMP9
24 vulvar benign neoplasm 10.4 ESR1 PGR
25 trigonitis 10.4 ESR1 PGR
26 vulvar leiomyoma 10.4 ESR1 PGR
27 villous adenocarcinoma 10.4 MMP2 MMP9
28 balanitis xerotica obliterans 10.4 PTGS2 VEGFA
29 spastic entropion 10.4 MMP2 MMP9
30 lentigo maligna melanoma 10.4 MMP2 MMP9
31 predominantly cortical thymoma 10.4 ESR1 PGR
32 infertility 10.4
33 breast medullary carcinoma 10.4 ESR1 PGR
34 angiokeratoma circumscriptum 10.4 MMP9 VEGFA
35 breast scirrhous carcinoma 10.4 ESR1 PGR
36 bartholin's gland benign neoplasm 10.4 ESR1 PGR
37 oncocytic breast carcinoma 10.4 ESR1 PGR
38 acute transverse myelitis 10.4 MMP2 MMP9
39 senile ectropion 10.4 MMP2 MMP9
40 intracystic papillary adenoma 10.4 PGR PRL
41 progesterone resistance 10.4 ESR1 PGR
42 endometrial squamous cell carcinoma 10.4 ESR1 PGR
43 cribriform carcinoma 10.4 ESR1 PGR
44 gingival hypertrophy 10.4 MMP9 TIMP2
45 endometrial mucinous adenocarcinoma 10.4 ESR1 PGR
46 adenoid basal cell carcinoma 10.3 ESR1 PGR
47 ischemic colitis 10.3 MMP2 MMP9 VEGFA
48 apocrine adenocarcinoma 10.3 ESR1 PGR
49 odontogenic myxoma 10.3 MMP2 MMP9 VEGFA
50 serous cystadenocarcinoma 10.3 MMP2 PGR VEGFA

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis
Sources

Symptoms & Phenotypes for Adenomyosis

About this section

Human phenotypes related to Adenomyosis:

33
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 33 HP:0001892
2 dysmenorrhea 33 HP:0100607
3 abnormality of the genitourinary system 33 HP:0000119

Symptoms via clinical synopsis from OMIM:

58
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM:

600458

MGI Mouse Phenotypes related to Adenomyosis:

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
2 growth/size/body region MP:0005378 10.33 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2
3 behavior/neurological MP:0005386 10.32 CYP19A1 ESR1 MMP9 NGF OXTR PGR
4 cardiovascular system MP:0005385 10.32 CDH1 CYP19A1 ESR1 MMP2 MMP9 NGF
5 immune system MP:0005387 10.32 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
6 integument MP:0010771 10.31 CDH1 CYP19A1 ESR1 GNRH1 MME MMP9
7 endocrine/exocrine gland MP:0005379 10.26 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 OXTR
8 hematopoietic system MP:0005397 10.24 CYP19A1 ESR1 GNRH1 MMP2 MMP9 PGR
9 nervous system MP:0003631 10.22 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9
10 digestive/alimentary MP:0005381 10.17 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
11 muscle MP:0005369 10.16 CYP19A1 ESR1 MMP2 MMP9 NGF OXTR
12 neoplasm MP:0002006 10.09 CDH1 ESR1 GNRH1 MMP2 MMP9 PGR
13 normal MP:0002873 10.06 CDH1 CYP19A1 ESR1 GNRH1 MMP2 NGF
14 liver/biliary system MP:0005370 10.02 CYP19A1 ESR1 GNRH1 MME PRL PTGS2
15 no phenotypic analysis MP:0003012 9.91 CDH1 ESR1 NGF OXTR PGR PTGS2
16 reproductive system MP:0005389 9.9 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
17 renal/urinary system MP:0005367 9.8 CYP19A1 ESR1 GNRH1 MMP9 PTGS2 ROCK1
18 skeleton MP:0005390 9.65 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9
19 vision/eye MP:0005391 9.17 CYP19A1 MMP2 MMP9 NGF PTGS2 ROCK1
Sources

Drugs & Therapeutics for Adenomyosis

About this section

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Ibuprofen Approved Phase 4 15687-27-1 3672
4
Dienogest Approved Phase 4,Not Applicable 65928-58-7
5
Nandrolone decanoate Approved, Illicit Phase 4,Not Applicable 360-70-3 9677
6
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4,Not Applicable 62-90-8 229455
7
Nandrolone Experimental, Investigational Phase 4,Not Applicable 434-22-0 9904
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
10 Contraceptives, Oral, Combined Phase 4,Phase 2,Early Phase 1,Not Applicable
11 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
12 Contraceptive Agents Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
13 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
14 Contraceptives, Oral Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
15 Ulipristal acetate Phase 4,Phase 2 126784-99-4
16 Anti-Inflammatory Agents Phase 4,Not Applicable
17 Cyclooxygenase Inhibitors Phase 4
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4
19 Antipyretics Phase 4
20 Analgesics Phase 4,Phase 3
21 Antirheumatic Agents Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
24 Contraceptive Agents, Male Phase 4,Not Applicable
25 Anabolic Agents Phase 4,Not Applicable
26 Androgens Phase 4,Not Applicable
27
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
28
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
29
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
30
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
31 Ramosetron Investigational Phase 3 132036-88-5
32
Lactitol Investigational Phase 2, Phase 3 585-86-4, 585-88-6 493591
33 Trace Elements Phase 3
34 Nutrients Phase 3
35 Micronutrients Phase 3
36 Antiemetics Phase 3,Not Applicable
37 Gastrointestinal Agents Phase 3,Not Applicable
38 Autonomic Agents Phase 3,Not Applicable
39 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Not Applicable
40 Serotonin Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Estrogens Phase 2, Phase 3,Early Phase 1,Not Applicable
43 Estrogen Receptor Antagonists Phase 2, Phase 3
44 Aromatase Inhibitors Phase 2, Phase 3
45 Steroid Synthesis Inhibitors Phase 2, Phase 3
46 Estrogen Antagonists Phase 2, Phase 3
47 Luteolytic Agents Phase 2, Phase 3
48 Contraceptives, Postcoital Phase 2, Phase 3
49
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
50
Levonorgestrel Approved, Investigational Phase 2,Early Phase 1,Not Applicable 17489-40-6, 797-63-7 13109

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Not yet recruiting NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
3 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
4 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Unknown status NCT02437175 Phase 3
5 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
6 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
7 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
8 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
9 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
10 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
11 Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Recruiting NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
12 Elastic Abdominal Binder After Open Abdominal Surgery for Benign Gynecologic Conditions Recruiting NCT03820115 Phase 3
13 Adenomyosis and Ulipristal Acetate Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
14 LNG-IUS for Treatment of Dysmenorrhea Completed NCT01601366 Phase 2 Combined oral contraceptives
15 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
16 Superior Hypogastric Nerve Block for Pain Control Post-UFE Completed NCT02270255 Phase 2 0.75% Ropivacaine;1% Xylocaine
17 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis Not yet recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
18 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
19 Vaginal Bromocriptine for Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
20 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
21 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180 Not Applicable
22 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
23 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
24 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 Not Applicable LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
25 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
26 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
27 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602 Not Applicable
28 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Unknown status NCT02086344 Not Applicable
29 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Unknown status NCT03006406 Not Applicable Long term GnRH-a (3.75mg)
30 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
31 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314 Not Applicable
32 Histopathological Diagnosis of Adenomyosis Completed NCT02340533 Not Applicable
33 Norwegian Adenomyosis Study I Completed NCT02201719
34 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648 Not Applicable
35 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309 Not Applicable
36 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
37 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
38 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
39 Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis Completed NCT03586063
40 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717 Not Applicable Dexamethasone;Normal saline
41 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471
42 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606 Not Applicable
43 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012 Not Applicable
44 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279 Not Applicable GnRH analogue
45 Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility Completed NCT02108665 Not Applicable
46 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Completed NCT01793584 Not Applicable
47 Electronic Catheter Stethoscope Completed NCT01463462
48 Effect of Salpingectomy During Conservative Hysterectomy Completed NCT01628432 Not Applicable
49 Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501 Not Applicable
50 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms Recruiting NCT02495311

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Sources

Genetic Tests for Adenomyosis

About this section
Sources

Anatomical Context for Adenomyosis

About this section

MalaCards organs/tissues related to Adenomyosis:

42
Uterus, Pituitary, Testes, Endothelial, Brain, Breast, Cervix
Sources

Publications for Adenomyosis

About this section

Articles related to Adenomyosis:

(show top 50) (show all 1188)
# Title Authors Year
1
Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. ( 30446308 )
2019
2
Transmembrane G protein-coupled receptor 30 gene polymorphisms and uterine adenomyosis in Korean women. ( 30626229 )
2019
3
Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis. ( 30675965 )
2019
4
What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease? ( 30722943 )
2019
5
In vivo Adenomyosis Tissue Sampling using a Transvaginal Ultrasound-guided Core Biopsy Technique for Research Purposes: Safety, Feasibility and Effectiveness. ( 30738919 )
2019
6
Diffuse massive adenomyosis and infertility. Is it possible to treat this condition? ( 30753160 )
2019
7
Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis. ( 30800671 )
2019
8
Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. ( 30828808 )
2019
9
Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis. ( 30832539 )
2019
10
Intrauterine cystic adenomyosis: Report of two cases. ( 30863769 )
2019
11
Adenomyosis: genetics of estrogen metabolism. ( 30878995 )
2019
12
Clinical efficacy of adenomyomectomy using "H" type incision combined with Mirena in the treatment of adenomyosis. ( 30882624 )
2019
13
Erratum: The rate of euploid miscarriage is increased in the setting of adenomyosis. ( 30895972 )
2019
14
Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. ( 29753309 )
2018
15
Clinical Usefulness of the Microbubble Contrast Agent SonoVue in Enhancing the Effects of High-Intensity Focused Ultrasound for the Treatment of Adenomyosis. ( 29689636 )
2018
16
Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. ( 29402199 )
2018
17
Adenomyosis and urinary system symptoms. ( 29655132 )
2018
18
ILK-induced epithelial-mesenchymal transition promotes the invasive phenotype in adenomyosis. ( 29409901 )
2018
19
The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. ( 29736395 )
2018
20
Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. ( 29447009 )
2018
21
Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: a Systematic Review. ( 29305234 )
2018
22
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? ( 29893860 )
2018
23
The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. ( 29040186 )
2018
24
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science. ( 29962279 )
2018
25
The Risk of Preterm Births Among Pregnant Women With Adenomyosis. ( 29363150 )
2018
26
Effects of pelvic endometriosis and adenomyosis on ciliary beat frequency and muscular contractions in the human fallopian tube. ( 29753325 )
2018
27
Adenomyosis and Endometrial Cancer: Literature Review. ( 29874641 )
2018
28
GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. ( 29922037 )
2018
29
The expression of MA1llerian inhibiting substance/anti-MA1llerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )
2018
30
Re: Pregnancy outcomes in patients with uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound Is the noninvasive nature of HIFU ablation for uterine fibroids and adenomyosis setting patients up for future operative delivery? ( 29405613 )
2018
31
Transvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis. ( 29320956 )
2018
32
The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. ( 29871559 )
2018
33
A sonographic classification and reporting system for diagnosing adenomyosis. ( 29790217 )
2018
34
Combination therapeutic effects of high intensity focused ultrasound and Metformin for the treatment of adenomyosis. ( 29434812 )
2018
35
Evaluation of NovaSure<sup>Ar</sup> global endometrial ablation in symptomatic adenomyosis: A longitudinal study with a 36 month follow-up. ( 29886317 )
2018
36
Anterior Focal Adenomyosis and Bladder Deep Infiltrative: is There a Link? ( 29432902 )
2018
37
Accuracy and Reproducibility of Sonoelastography for the Assessment of Fibroids and Adenomyosis, with Magnetic Resonance Imaging as Reference Standard. ( 29784438 )
2018
38
A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. ( 29344938 )
2018
39
Endophytic-Type Endometrial Cancer with Adenomyosis Successfully Diagnosed with Hysteroscopic Endometrial Biopsy Using an 8.3-mm Operative Resectoscope: A Case Report. ( 29928209 )
2018
40
Uterine adenomyosis and adenomyoma: the surgical approach. ( 29566853 )
2018
41
Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. ( 29626678 )
2018
42
Long-term dienogest administration in patients with symptomatic adenomyosis. ( 29845696 )
2018
43
Conservative surgery of diffuse adenomyosis with TOUA: Single surgeon experience of one hundred sixteen cases and report of fertility outcomes. ( 29699636 )
2018
44
Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. ( 29304094 )
2018
45
Berberine inhibits growth and inflammatory invasive phenotypes of ectopic stromal cells: Imply the possible treatment of adenomyosis. ( 29752208 )
2018
46
Associations between a single nucleotide polymorphism of stress-induced phosphoprotein 1 and endometriosis/adenomyosis. ( 29673672 )
2018
47
Conservative surgery of uterine adenomyosis via laparoscopic versus laparotomic approach in a single institution. ( 29845687 )
2018
48
Re: A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study Is the cost-effectiveness of HIFU for adenomyosis and fibroids feasible? ( 29405542 )
2018
49
Effect of pretreatment with gonadotropin-releasing hormone analog GnRH-I+ on high-intensity focused ultrasound ablation for diffuse adenomyosis: a preliminary study. ( 29447020 )
2018
50
Coexistence of adenomyosis, adenocarcinoma, endometrial and myometrial lesions in resected uterine specimens. ( 30101029 )
2018
Sources

Variations for Adenomyosis

About this section
Sources

Expression for Adenomyosis

About this section
Search GEO for disease gene expression data for Adenomyosis.
Sources

Pathways for Adenomyosis

About this section

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
GPCR Pathway 65
Show member pathways
 13.56 ESR1 GNRH1 MMP2 MMP9 NGF PTGS2
2
Nanog in Mammalian ESC Pluripotency 65
Show member pathways
 13.16 CDH1 ESR1 GNRH1 NGF TIMP2 VEGFA
3
Circadian entrainment 38
Show member pathways
 12.92 ESR1 MMP2 MMP9 PGR VEGFA
4
Glioma 38
Show member pathways
 12.58 CDH1 ESR1 MMP2 MMP9 VEGFA
5
EPH-Ephrin signaling 67
Show member pathways
 12.48 MMP2 MMP9 ROCK1 VEGFA
6
MicroRNAs in cancer 38
12.39 MMP9 PTGS2 ROCK1 VEGFA
7
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.29 ESR1 PTGS2 ROCK1 VEGFA
8
Proteoglycans in cancer 38
12.02 ESR1 MMP2 MMP9 ROCK1 VEGFA
9
Integrated Breast Cancer Pathway 1
12 CDH1 CYP19A1 ESR1 VEGFA
10
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.96 CDH1 GNRH1 NGF TIMP2
11
Adhesion 4
11.91 CDH1 MMP2 MMP9
12
Pathways in cancer 38
11.89 CDH1 ESR1 MMP2 MMP9 PTGS2 ROCK1
13
Signaling by ERBB4 67
Show member pathways
 11.85 ESR1 PGR PRL
14
Interleukin-4 and 13 signaling 67
11.84 MMP2 MMP9 PTGS2 VEGFA
15
Matrix Metalloproteinases 1
Show member pathways
 11.79 MMP2 MMP9 TIMP2
16
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.68 CDH1 MMP2 MMP9
17
G-protein signaling_RhoA regulation pathway 23
11.62 GNRH1 NGF ROCK1 TIMP2
18
Angiogenesis (CST) 4
11.62 MMP2 MMP9 PTGS2 TIMP2
19
AGE/RAGE pathway 1
11.59 MMP2 MMP9 ROCK1
20
Colorectal Cancer Metastasis 65
11.57 CDH1 MMP2 MMP9 PTGS2 VEGFA
21
Cell adhesion_ECM remodeling 23
11.54 MMP2 MMP9 TIMP2
22
Celecoxib Pathway, Pharmacodynamics 62
11.51 MMP9 PTGS2 VEGFA
23
amb2 Integrin signaling 1
11.42 MMP2 MMP9 ROCK1
24
Bladder cancer 38 1
11.42 CDH1 MMP2 MMP9 VEGFA
25
Aryl Hydrocarbon Receptor 1
11.4 ESR1 PTGS2 VEGFA
26
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.26 MMP2 MMP9 PTGS2 VEGFA
27
A-beta Pathways: Uptake and Degradation 66
11.18 MME MMP2 MMP9
28
Plasma membrane estrogen receptor signaling 1
11.05 ESR1 MMP2 MMP9
29
Angiogenesis (WikiPathways) 1
10.99 MMP9 TIMP2 VEGFA
30
A-beta Pathways: Plaque Formation and APP Metabolism 66
10.94 MME MMP2 MMP9
31
G-protein signaling_Rap2B regulation pathway 23
10.91 CDH1 GNRH1 NGF ROCK1 TIMP2
32
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 62
10.13 CYP19A1 ESR1
Sources

GO Terms for Adenomyosis

About this section

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 GNRH1 MMP2 MMP9 NGF PRL TIMP2
2 extracellular region GO:0005576 9.28 CDH1 GNRH1 MMP2 MMP9 NGF PRL
3 extracellular matrix GO:0031012 9.26 MMP2 MMP9 TIMP2 VEGFA

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.96 GNRH1 MMP9 NGF PTGS2 VEGFA
2 cytokine-mediated signaling pathway GO:0019221 9.87 MMP2 MMP9 PTGS2 VEGFA
3 female pregnancy GO:0007565 9.76 GNRH1 OXTR PRL
4 response to organic substance GO:0010033 9.75 CDH1 PTGS2 TIMP2
5 ephrin receptor signaling pathway GO:0048013 9.71 MMP2 MMP9 ROCK1
6 memory GO:0007613 9.7 NGF OXTR PTGS2
7 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.67 NGF PTGS2 VEGFA
8 extracellular matrix disassembly GO:0022617 9.65 MMP2 MMP9 TIMP2
9 response to cytokine GO:0034097 9.63 OXTR PTGS2 TIMP2
10 androgen metabolic process GO:0008209 9.61 CYP19A1 ESR1
11 macrophage differentiation GO:0030225 9.61 MMP9 VEGFA
12 mammary gland alveolus development GO:0060749 9.6 ESR1 VEGFA
13 estrous cycle GO:0044849 9.59 GNRH1 OXTR
14 lactation GO:0007595 9.58 OXTR PRL VEGFA
15 embryo implantation GO:0007566 9.54 MMP2 MMP9 PTGS2
16 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.51 ROCK1 TIMP2
17 mammary gland development GO:0030879 9.5 CYP19A1 PGR PRL
18 response to drug GO:0042493 9.46 CDH1 OXTR PTGS2 TIMP2
19 response to angiotensin GO:1990776 9.43 PTGS2 ROCK1
20 response to organic cyclic compound GO:0014070 9.43 GNRH1 OXTR PTGS2
21 ovulation cycle GO:0042698 9.25 GNRH1
22 response to estradiol GO:0032355 9.13 ESR1 OXTR PTGS2
23 uterus development GO:0060065 8.8 CYP19A1 ESR1 HOXA10

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.65 CDH1 CYP19A1 ESR1 MME MMP2 MMP9
2 metalloendopeptidase activity GO:0004222 9.33 MME MMP2 MMP9
3 metalloendopeptidase inhibitor activity GO:0008191 9.26 NGF TIMP2
4 zinc ion binding GO:0008270 9.1 ESR1 MME MMP2 MMP9 PGR TIMP2
Sources

Sources for Adenomyosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....